Awaiting development: Guidance and quality standards

Showing 1 to 9 of 9

Guidance and quality standards awaiting development
Title	Type
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]	Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]	Technology appraisal guidance
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249	Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491	Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949	Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]	Technology appraisal guidance
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment TS ID 12121	Technology appraisal guidance
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443	Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance